恶性肿瘤患者的庆大霉素药代动力学
Gentamicin pharmacokinetics in patients with malignancies.
作者信息
Bertino J S, Booker L A, Franck P, Rybicki B
机构信息
Department of Pharmacy Services, Mary Imogene Bassett Hospital, Cooperstown, New York 13326.
出版信息
Antimicrob Agents Chemother. 1991 Jul;35(7):1501-3. doi: 10.1128/AAC.35.7.1501.
The pharmacokinetics of gentamicin were investigated in 880 patients with leukemia (24 patients), other malignancies (211 patients), or no malignancies (645 patients) by using data collected by our Clinical Pharmacy Service. A significant difference was seen in the initial calculated creatinine clearance between the patients with leukemia and the other two groups. No differences in gentamicin pharmacokinetics were seen in patients with other malignancies versus those with no malignancies. Patients with leukemia had significantly faster drug clearance compared with those in the other two groups. A poor predictive value was found for total body clearance of gentamicin versus the initial calculated creatinine clearance in all groups. Multiple logistic regression analysis showed that only the initial calculated creatinine clearance differed in the leukemic group compared with those in the other patients. Our data suggest that no pharmacokinetic difference exists for gentamicin in patients with malignancies.
利用我们临床药学服务收集的数据，对880例白血病患者（24例）、其他恶性肿瘤患者（211例）或无恶性肿瘤患者（645例）的庆大霉素药代动力学进行了研究。白血病患者与其他两组患者在初始计算的肌酐清除率上存在显著差异。其他恶性肿瘤患者与无恶性肿瘤患者的庆大霉素药代动力学未见差异。与其他两组患者相比，白血病患者的药物清除明显更快。在所有组中，庆大霉素的总体清除率与初始计算的肌酐清除率的预测价值较差。多元逻辑回归分析表明，与其他患者相比，白血病组仅初始计算的肌酐清除率有所不同。我们的数据表明，恶性肿瘤患者的庆大霉素药代动力学不存在差异。
Zotero 插件